KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Capital Leases (2016 - 2018)

Gsk has reported Capital Leases over the past 3 years, most recently at $56.6 million for Q4 2018.

  • For Q4 2018, Capital Leases fell 0.83% year-over-year to $56.6 million; the TTM value through Dec 2018 reached $56.6 million, down 0.83%, while the annual FY2018 figure was $58.8 million, 2.93% up from the prior year.
  • Capital Leases for Q4 2018 was $56.6 million at Gsk, down from $57.1 million in the prior quarter.
  • Over five years, Capital Leases peaked at $57.1 million in Q4 2017 and troughed at $51.0 million in Q4 2016.
  • A 3-year average of $54.9 million and a median of $56.6 million in 2018 define the central range for Capital Leases.
  • Biggest five-year swings in Capital Leases: rose 12.0% in 2017 and later dropped 0.83% in 2018.
  • Year by year, Capital Leases stood at $51.0 million in 2016, then grew by 12.0% to $57.1 million in 2017, then fell by 0.83% to $56.6 million in 2018.
  • Business Quant data shows Capital Leases for GSK at $56.6 million in Q4 2018, $57.1 million in Q4 2017, and $51.0 million in Q4 2016.